# US 2010/0169995 A1 · Targeted gene disruptions in the iqgap2 gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0169995 A1
- Document ID: US20100169995A1
- Status: Published application
- Kind: A1
- Application number: 12/640,876
- Filed: 2009-12-17
- Published: 2010-07-01
- Earliest claimed: 2008-12-17
- Assignees: The Research Foundation of State University of New York
- Inventors: Valentina Schmidt; Wadie F. Bahou
- Web page: https://patentgrep.com/patent/US20100169995A1

## CPC

- A01K 67/0276: Knock-out vertebrates
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61P 35/00: Antineoplastic agents
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- G01N 33/57525: of the liver or pancreas
- A01K 2217/058: due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2800/204: of bacterial origin, e.g. BAC
- G01N 2500/10: involving cells
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides a non-human mammal or a cell line that has a targeted gene disruption in an endogenous Iqgap2 gene. The invention also provides methods of identifying a compound as a therapeutic agent for the treatment of hepatocellular carcinoma and methods of treating or preventing hepatocellular carcinoma.

## Claims

### Claim 1

A non-human mammal, which comprises a targeted gene disruption in an endogenous Iqgap2 gene.

### Claim 2 (depends on 1)

The non-human mammal of claim 1, which is homozygous for the targeted gene disruption.

### Claim 3

A non-human mammal, which comprises a transgene that encodes an RNA that inhibits expression of an endogenous Iqgap2 gene.

### Claim 4 (depends on 3)

The non-human mammal of claim 3, wherein the RNA is selected from the group consisting of an antisense RNA, and a siRNA.

### Claim 5

A non-human mammal, which comprises a transgene that overexpresses an Iqgap1 gene.

### Claim 6 (depends on 1, 2, 3, 4)

The non-human mammal of claims 1 to 4, which comprises a null allele of the endogenous Iqgap1 gene.

### Claim 7 (depends on 1, 2, 3, 4)

The non-human mammal of claims 1 to 4, which is homozygous for a null allele of the endogenous Iqgap1 gene.

### Claim 8 (depends on 6, 7)

The non-human mammal of claim 6 or 7, wherein the null allele is a targeted disruption in an endogenous Iqgap1 gene.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The non-human mammal of any one of claims 1 to 5, which exhibits an age-dependent increase in apoptosis of hepatocytes.

### Claim 10 (depends on 1, 2, 3, 4, 5)

The non-human mammal of any one of claims 1 to 5, which exhibits an age-dependent increase in hepatocellular carcinoma.

### Claim 11 (depends on 6, 7, 8, 9, 10)

The non-human mammal of any one of claims 6 to 10, which exhibits a reduction in age-dependent apoptosis or hepatocellular carcinoma associated with reduced Iqgap2 levels.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The transgenic non-human mammal of any one of claims 1 to 11, wherein the transgenic non-human mammal is a mouse.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A cell isolated from the transgenic non-human mammal of any one of claims 1 to 12.

### Claim 14 (depends on 13)

The isolated cell of claim 13, which is a hepatocyte, fibroblast, myocyte, adipocyte, lymphocyte, megacaryocyte, or platelet.

### Claim 15 (depends on 13, 14)

The cell of claim 13 or 14, which overexpresses Iqgap1.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A cell line derived from the non-human mammal of any of claims 1 to 12.

### Claim 17

A cell line which comprises an inactivated endogenous Iqgap2 gene.

### Claim 18 (depends on 17)

The cell line of claim 17, which is homozygous for the inactivated endogenous Iqgap2 gene.

### Claim 19 (depends on 17)

The cell line of claim 17, wherein the endogenous Iqgap2 gene is inactivated by a targeted disruption.

### Claim 20 (depends on 17)

The cell line of claim 17, wherein the endogenous Iqgap2 gene is inactivated by a small interfering RNA, a microRNA, or an anti-sense RNA.

### Claim 21 (depends on 17, 18, 19, 20)

The cell line of any one of claims 17 to 20, which further comprises an inactivated Iqgap1 gene.

### Claim 22 (depends on 17, 18, 19, 20)

The cell line of any one of claims 17 to 20, which is engineered to overexpress Iqgap1.

### Claim 23 (depends on 21)

The cell line of claim 21, wherein the genome of the cell line comprises a null allele of the endogenous Iqgap1 gene.

### Claim 24 (depends on 17)

The cell line of claim 17 wherein the cell line is an embryonic stem cell line.

### Claim 25

A targeting construct comprising a first polynucleotide sequence homologous to a first portion of an endogenous Iqgap2 gene, a second polynucleotide sequence homologous to a second portion of the endogenous Iqgap2 gene, and a selectable marker located between the first and second polynucleotide sequences.

### Claim 26 (depends on 25)

The targeting construct of claim 25, wherein the Iqgap2 gene is a mouse gene.

### Claim 27

A method of producing a transgenic non-human mammal comprising a disruption in an endogenous Iqgap2 gene, comprising:
a) introducing a targeting construct capable of disrupting the endogenous Iqgap2 gene into an embryonic stem cell of the mammal;
b) selecting an embryonic stem cell that has undergone homologous recombination
c) introducing the recombinant embryonic stem cell into a blastocyst;
d) implanting the blastocyst into the mammal, wherein the mammal gives birth to a chimeric mammal; and
e) breeding the chimeric mammal to produce the transgenic mammal,
wherein when the disruption is homozygous, the transgenic mammal lacks production of a functional IQGAP2 protein.

### Claim 28 (depends on 27)

The method of claim 27, wherein the Iqgap1 gene is overexpressed in hepatocytes of the transgenic mammal

### Claim 29

A method of identifying a compound as a therapeutic agent for the treatment of hepatocellular carcinoma, comprising:
contacting the compound with a test cell that underexpresses Iqgap2, wherein Iqgap1 is overexpressed, and
identifying the compound as a therapeutic agent for treatment of hepatocellular carcinoma if IQGAP1 activity is reduced in response to the compound.

### Claim 30 (depends on 29)

The method of claim 29, wherein Iqgap1 is overexpressed in response to Iqgap2 underexpression.

### Claim 31 (depends on 29)

The method of claim 29, wherein the test cell is engineered to overexpress Iqgap1.

### Claim 32

A method of identifying a compound as a therapeutic agent for the treatment of hepatocellular carcinoma, comprising:
contacting the compound with a test cell that overexpresses Iqgap1, and
identifying the compound as a therapeutic agent for treatment of hepatocellular carcinoma if IQGAP1 activity is reduced in response to the compound.

### Claim 33 (depends on 29, 32)

The method of claim 29 or 32, wherein the test cell is a hepatocyte.

### Claim 34 (depends on 29, 32)

The method of claim 29 or 32, wherein the IQGAP1 activity is evaluated by observing the level of Iqgap1 expression using an Iqgap1 reporter gene construct.

### Claim 35

A method of identifying a compound as a therapeutic agent for the treatment of hepatocellular carcinoma, comprising:
providing a non-human mammal which comprises a targeted gene disruption in an endogenous Iqgap2 gene and exhibits an age-dependent increase in apoptosis of hepatocytes;
administering the compound to the non-human mammal, and
identifying the compound as a therapeutic agent if it reduces the age-dependent increase in apoptosis.

### Claim 36

A method of identifying a compound as a therapeutic agent for the treatment of hepatocellular carcinoma, comprising:
providing a non-human mammal which comprises a targeted gene disruption in an endogenous Iqgap2 gene and exhibits an age-dependent increase in hepatocellular carcinoma;
administering the compound to the non-human mammal, and
identifying the compound as a therapeutic agent if it reduces the age-dependent increase in hepatocellular carcinoma.

### Claim 37

A model of human hepatocellular carcinoma comprising hepatocytes in which Iqgap2 is underexpressed.

### Claim 38 (depends on 37)

The model of claim 37, wherein the reduction in the expression of Iqgap2 is accomplished by creating a null allele of the endogenous Iqgap2 gene.

### Claim 39 (depends on 37)

The model of claim 37, wherein the null allele of the endogenous Iqgap2 is homozygous.

### Claim 40

A method of treating or preventing hepatocellular carcinoma comprising administering an agent that decreases Iqgap1 function in hepatocytes.

### Claim 41 (depends on 40)

The method of claim 40, wherein the agent that decreases Iqgap1 function is an siRNA.

### Claim 42 (depends on 40)

The method of claim 40, wherein the agent that decreases Iqgap1 function is a synthetic blocking peptide.

### Claim 43 (depends on 42)

The method of claim 42, wherein synthetic blocking peptide is directed against IQGAP1 domains selected from the group consisting of: actin-binding calponin homology domain, SH3-mimicking domain, calmodulin-binding domains, and GTPase-binding domain.

### Claim 44

A method of treating or preventing hepatocellular carcinoma by administering an agent that enhances Iqgap2 function in hepatocytes.

### Claim 45 (depends on 44)

The method of claim 44, wherein the agent comprises a vector that expresses Iqgap2.

### Claim 46 (depends on 45)

The method of claim 45, wherein the Iqgap2 is expressed from a liver-specific promoter.

### Claim 47 (depends on 46)

The method of claim 46, wherein the liver-specific promoter is selected from the group consisting of promoter from the genes: albumin, α1-antitrypsin (AAT), phosphoenolpyruvate carboxykinase (PEPCK) and fatty acid binding protein (FABP).

### Claim 48 (depends on 44)

The method of claim 44, wherein the agent comprises a methylation inhibitor.

### Claim 49 (depends on 48)

The method of claim 48, wherein the methylation inhibitor is a nucleoside inhibitor.

### Claim 50 (depends on 49)

The method of claim 49, wherein the nucleoside inhibitor is selected from the group consisting of 5-azacytidine, 5-aza-2′-deoxy-cytidine, zebularine, and 5-fluoro-2′-deoxycytidine.

### Claim 51 (depends on 48)

The method of claim 48, wherein the methylation inhibitor is a non-nucleoside inhibitor.

### Claim 52 (depends on 48)

The method of claim 48, wherein the non-nucleoside inhibitor is selected from the group consisting of procainamide, and hydralazine.
